Aura Biosciences Company Insiders

AURA Stock  USD 8.67  0.22  2.47%   
Aura Biosciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Aura Biosciences suggests that vertually all insiders are panicking. Aura Biosciences employs about 88 people. The company is managed by 16 executives with a total tenure of roughly 206 years, averaging almost 12.0 years of service per executive, having 5.5 employees per reported executive.

Aura Biosciences' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-11-18Janet Jill HopkinsDisposed 11822 @ 9.36View
2024-10-29Los Pinos Elisabet DeDisposed 9200 @ 10.74View
2024-10-18Los Pinos Elisabet DeDisposed 24992 @ 12.04View
2024-10-16Mark PlavsicDisposed 7383 @ 9.85View
2024-01-23Los Pinos Elisabet DeDisposed 15853 @ 7.64View
Monitoring Aura Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aura Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.

Aura Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.3022) % which means that it has lost $0.3022 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5099) %, meaning that it created substantial loss on money invested by shareholders. Aura Biosciences' management efficiency ratios could be used to measure how well Aura Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of December 17, 2024, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, Aura Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.3 M, whereas Total Assets are forecasted to decline to about 153.6 M.
As of December 17, 2024, Common Stock Shares Outstanding is expected to decline to about 34.6 M. In addition to that, Net Loss is expected to decline to about (55.5 M)

Aura Biosciences Workforce Comparison

Aura Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,981. Aura Biosciences holds roughly 88.0 in number of employees claiming about 4% of equities under Health Care industry.

Aura Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aura Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aura Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aura Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.4
4
10
 50,123 
 129,204 
2024-09-01
1.0
1
1
 5,474 
 5,474 
2024-03-01
1.2
6
5
 645,000 
 201,947 
2023-12-01
1.8333
11
6
 2,065,367 
 32,020 
2022-12-01
0.75
3
4
 1,257,000 
 10,508 
2021-12-01
1.5625
25
16
 10,642,713 
 3,686,787 
2003-09-01
2.0
2
1
 6,500,000 
 0.00 

Aura Biosciences Notable Stakeholders

An Aura Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aura Biosciences often face trade-offs trying to please all of them. Aura Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aura Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Julie FederSecretary CFOProfile
Richard MountfieldSenior QualityProfile
Patrick NealonSenior OperationsProfile
CPE MBAChief RDProfile
Jill MDChief DevelopmentProfile
Amy ElazzouziInterim OfficerProfile
Paulo CarvalhoVP OperationsProfile
Bruce MDSenior OncologyProfile
Conor KilroyGeneral SecretaryProfile
Elisabet PinosCEO, FounderProfile
Mark RoschChief OfficerProfile
Michele MBAVP ChainProfile
Anthony MDTherapeutic OncologyProfile
Joseph LyonsVP HRProfile
Mark DVMChief OfficerProfile
Sabine BrookmanMaySenior OncologyProfile

About Aura Biosciences Management Performance

The success or failure of an entity such as Aura Biosciences often depends on how effective the management is. Aura Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aura management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aura management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.30)(0.31)
Return On Capital Employed(0.35)(0.37)
Return On Assets(0.30)(0.31)
Return On Equity(0.34)(0.32)
Please note, the presentation of Aura Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aura Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Aura Biosciences' management manipulating its earnings.

Aura Biosciences Workforce Analysis

Traditionally, organizations such as Aura Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aura Biosciences within its industry.

Aura Biosciences Manpower Efficiency

Return on Aura Biosciences Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee868.3K
Net Loss Per Executive4.8M
Working Capital Per Employee2.5M
Working Capital Per Executive13.7M

Complementary Tools for Aura Stock analysis

When running Aura Biosciences' price analysis, check to measure Aura Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aura Biosciences is operating at the current time. Most of Aura Biosciences' value examination focuses on studying past and present price action to predict the probability of Aura Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aura Biosciences' price. Additionally, you may evaluate how the addition of Aura Biosciences to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets